Cebranopadol
chemical compound
Cebranopadol, also known by its developmental code names TRN-228 and formerly GRT-6005, is an experimental atypical opioid analgesic which is under development for the treatment of various types of pain as well as for treatment of substance-related disorders. It is taken orally.
Side effects of cebranopadol include nausea, vomiting, constipation, somnolence, euphoria, and respiratory depression, among others. The drug acts as a non-selective opioid receptor agonist, including as a dual μ-opioid receptor and nociceptin receptor full agonist and to a lesser extent as a κ-opioid receptor partial agonist. In relation to its multi-target profile, namely its nociceptin receptor agonism, cebranopadol shows atypical effects and certain potential advantages compared to selective μ-opioid receptor agonists like morphine, such as less misuse potential and respiratory depression. On the other hand, it has a long half-life in humans and still carries risk of misuse similarly to other opioids.
Cebranopadol was first described in the patent literature by 2002 and in the scientific literature by 2013. As of August 2025, it has completed multiple phase 3 clinical trials for treatment of pain. According to its developer, a New Drug Application (NDA) is to be submitted in the near future. As a dual μ-opioid and nociceptin receptor agonist, cebranopadol is a potential first-in-class medication.
This brief starts where responsible research should: with the source description of “Cebranopadol” as chemical compound. Everything that follows is an evidence route, not borrowed authority.
Why this record matters
The subject matters to the science & nature register because the source frames it as chemical compound. Its deeper value depends on whether names, dates, institutions and citations support that framing.
Stable identifiers, scientific names and standards terminology offer the best bridge between this overview and specialist evidence. The source revision retrieved here is dated Aug 11, 2026. The linked authority identifier is Q19596315. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2002, 2013 and 2025.
Current terminology should not be projected backward without checking the classification used when the underlying evidence was created. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Cebranopadol”, its source revision and the description used here.
- Expand the search: follow Cebranopadol primary sources, Cebranopadol archive and Cebranopadol research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Cebranopadol”?
- Has classification or technical consensus changed since the cited source?
- Is the terminology current, historical or disputed?
Search terms from this dossier
This entry incorporates text from “Cebranopadol” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.